Genprex Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Genprex Advances Diabetes Program With Addition Of Research Focused On Non-Viral Delivery System
Brief: Genprex Provides Update On Diabetes Gene Therapy Program
Brief: Genprex Inc Receives Nasdaq Notice For Non-Compliance With Equity Requirement
Genprex Inc reports results for the quarter ended September 30 - Earnings Summary
Genprex Inc expected to post a loss of 68 cents a share - Earnings Preview
Genprex Inc expected to post a loss of $1.93 a share - Earnings Preview
Brief: Genprex Inc Regains Compliance With NASDAQ Minimum Bid Price Requirement
Brief: Genprex Receives Safety Review Committee Approval
Brief: Genprex Receives Letter From Nasdaq On Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer
Brief: Genprex Appoints Jose Moreno Toscano as Chairman of the Board of Directors
Founder And Chief Executive Officer, Rodney Varner
Brief: Genprex Expands Clinical Trial Sites For Acclaim-3 Clinical Study Of Reqorsa Therapy In Combination With Tecentriq To Treat Small Cell Lung Cancer
Genprex Inc reports results for the quarter ended in December - Earnings Summary
Genprex Inc expected to post a loss of $3.93 a share - Earnings Preview
Brief: Genprex Announces Closing Of $6.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Genprex Receives Notice Of Patent Grant For Korean Patent Claiming Reqorsa® Immunogene Therapy With Pd-1 And Pd-L1 Antibodies To Treat Cancers
Brief: Genprex Inc Received A Letter From Nasdaq Stating Co Has Regained Compliance With Minimum Bid Price Requirement